医学
低温消融
冷冻疗法
胶质母细胞瘤
回顾性队列研究
外科
无进展生存期
磁共振成像
放射外科
总体生存率
放射科
放射治疗
内科学
癌症研究
烧蚀
作者
H. Cébula,Julien Garnon,Julien Todeschi,Georges Noël,Benoît Lhermitte,Charles-Henry Mallereau,Salvatore Chibbaro,Hélène Burckel,Roland Schött,Michel de Mathelin,Afshin Gangi,F. Proust
出处
期刊:Neurochirurgie
[Elsevier]
日期:2022-04-01
卷期号:68 (3): 267-272
被引量:1
标识
DOI:10.1016/j.neuchi.2021.11.004
摘要
Glioblastoma invariably recurs after primary Stupp tumor therapy and portends a poor prognosis. Cryoablation is a well-established treatment strategy for extra-cranial tumors. The safety and efficacy of interventional MR-guided cryoablation (iMRgC) has not been explored in recurrent glioblastoma.A retrospective analysis of data collected over a period of 24 months was performed. The inclusion criteria were: (I) recurrent glioblastoma despite Stupp protocol; (II) MRI followed by histological confirmation of recurrent glioblastoma; (III) location allowing iMRgC followed by microsurgical resection; and (IV) patient's consent. The primary objective was to assess feasibility in terms of complications. The secondary objective was to analyze progression-free survival (PFS), post-iMRgC survival and overall survival (OS).The study included 6 patients, with a mean age of 67±7.6 years [range, 54-70 years]. No major complications were observed. Median PFS was 7.5 months [IQR 3.75-9.75] and 6-month PFS was 50%. Median post-iMRgC survival was 9 months [IQR 7.5-15.25] and 6-month post-iMRgC survival was 80%. Median OS was 22.5 months [IQR 21.75-30].iMRgC for recurrent glioblastoma demonstrated a good safety profile, with no major complications. Our data suggest improved PFS and OS.No. IRB00011687 retrospectively registred on July 7th 2021.
科研通智能强力驱动
Strongly Powered by AbleSci AI